Sagent Behavioral Health Mother Baby Program Comment on the FDA’s Panel on Antidepressants and Pregnancy
On July 21, 2025, the United States Food and Drug Administration convened a panel to discuss the use of selective serotonin reuptake inhibitors (SSRIs) during pregnancy. The panel, unfortunately, biasedly focused on the risks of the medication and did not address the risks of mental health.
This letter aims to clarify...




